Results From Phase I M16-106 Study of Venetoclax Plus Navitoclax in Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Commentary from Jeff Sharman, MD, on noncovalent BTK inhibitors in patients with CLL and progression on currently available BTK inhibitors, from Clinical Care Options (CCO)

Jeff P. Sharman, MD Released: September 25, 2020

Interactive on-demand Webcast featuring expert insights on the newest data influencing best practice for managing patients with CLL

Farrukh T. Awan, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: September 24, 2020 Expired: September 23, 2021

Ian W. Flinn, MD, PhD; Shaji Kumar, MD; and Farhad Ravandi, MD, discuss important presentations in hematologic malignancies from the virtual ASCO 2020 as reported by Clinical Care Options (CCO)

Ian W. Flinn, MD, PhD Shaji Kumar, MD Farhad Ravandi, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: September 23, 2020 Expired: September 22, 2021

Commentary from Danielle M. Brander, MD, on the importance of prognostic testing of key markers in patients with CLL, as reported by Clinical Care Options (CCO)

Danielle Brander, MD Released: September 22, 2020